Indore Online Journal

Heart Failure Market Size in the 7MM is expected to grow by 2034 | DelveInsight

 Breaking News
  • No posts were found

Heart Failure Market Size in the 7MM is expected to grow by 2034 | DelveInsight

April 16
17:20 2024
Heart Failure Market Size in the 7MM is expected to grow by 2034 | DelveInsight

DelveInsight’s “Heart Failure Market Insights, Epidemiology, and Market Forecast — 2034” report delivers an in-depth understanding of the Heart Failure, historical and forecasted epidemiology as well as the Heart Failure market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

 

Key Takeaways from the Heart Failure Market Research Report

  • The increase in Heart Failure Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
  • As per DelveInsight analysis, the Heart Failure market is anticipated to witness growth at a considerable CAGR.
  • The leading Heart Failure Companies working in the market include Roche, Pfizer, Novo Nordisk, Merck & Co, AstraZeneca, GlaxoSmithKline, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Novartis, Sanofi, Johnson & Johnson, Takeda Pharmaceutical Company Limited, AbbVie, Gilead Sciences, Amgen, Biogen, Moderna, Regeneron Pharmaceuticals, and Vertex Pharmaceuticals, and many others.
  • Promising Heart Failure Pipeline Therapies in the various stages of development include CXL-1020, Strata 1 CXL-1020, Ularitide, JTT-861 Capsules, JARDIANCE®, Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Bisoprolol, Empagliflozin, Lixivaptan, and others.
  • April 2024: AstraZeneca announced a study of Phase 2 clinical trials for AZD3427. This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2.
  • April 2024: Bayer announced a study of Phase 3 clinical trials for Finerenone (BAY94-8862). The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiovascular death (generally meaning death due to disease of the heart or blood vessels) and total Heart Failure (HF) events, including HF hospitalization and urgent visits for HF(generally meaning a hospital stay or urgent presentation to a healthcare unit due to worsening symptoms of heart failure) in patients suffering from HF with an ejection fraction greater than or equal to 40%.

 

Discover which therapies are expected to grab the Heart Failure Market Share @ Heart Failure Market Outlook

 

Heart Failure Overview 

Heart failure, also known as congestive heart failure, is a medical condition in which the heart is unable to pump blood efficiently enough to meet the body’s needs. This inefficiency can result from various underlying conditions that damage or overwork the heart, such as coronary artery disease, high blood pressure, or previous heart attacks.

 

Heart Failure Epidemiology Insights

The epidemiology section of Heart Failure offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

 

Download the report to understand which factors are driving Heart Failure Epidemiology trends @ Heart Failure Epidemiological Insights

 

Heart Failure Drugs Market

The Heart Failure Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Heart Failure signaling in Heart Failure are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Heart Failure Treatment Market Landscape

The Heart Failure treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Heart Failure has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about Heart Failure treatment guidelines, visit @ Heart Failure Treatment Market Landscape

 

Heart Failure Market Outlook

The report’s outlook on the Heart Failure market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Heart Failure therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Heart Failure drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Heart Failure market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Heart Failure Drugs Uptake

The drug chapter of the Heart Failure report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Heart Failure.

 

Major Heart Failure Companies

Several Heart Failure Companies working in the market include Roche, Pfizer, Novo Nordisk, Merck & Co, AstraZeneca, GlaxoSmithKline, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Novartis, Sanofi, Johnson & Johnson, Takeda Pharmaceutical Company Limited, AbbVie, Gilead Sciences, Amgen, Biogen, Moderna, Regeneron Pharmaceuticals, and Vertex Pharmaceuticals, and many others

 

Learn more about the FDA-approved drugs for Heart Failure @ Drugs for Heart Failure Treatment

 

Scope of the Heart Failure Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Heart Failure Companies-  Roche, Pfizer, Novo Nordisk, Merck & Co, AstraZeneca, GlaxoSmithKline, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Novartis, Sanofi, Johnson & Johnson, Takeda Pharmaceutical Company Limited, AbbVie, Gilead Sciences, Amgen, Biogen, Moderna, Regeneron Pharmaceuticals, and Vertex Pharmaceuticals, and many others
  • Heart Failure Pipeline Therapies- CXL-1020, Strata 1 CXL-1020, Ularitide, JTT-861 Capsules, JARDIANCE®, Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Bisoprolol, Empagliflozin, Lixivaptan, and others.
  • Heart Failure Market Dynamics: Heart Failure Market Drivers and Barriers
  • Heart Failure Market Access and Reimbursement, Unmet Needs, KOL’s Views, and Analyst’s Views

 

Discover more about Heart Failure Drugs in development @ Heart Failure Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Executive Summary of Heart Failure

3. Competitive Intelligence Analysis for Heart Failure

4. Heart Failure: Market Overview at a Glance

5. Heart Failure: Disease Background and Overview

6. Patient Journey

7. Heart Failure Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Heart Failure Unmet Needs

10. Key Endpoints of Heart Failure Treatment

11. Heart Failure Marketed Products

12. Heart Failure Emerging Therapies

13. Heart Failure: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Heart Failure

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories